Revascularization Cuts Mortality, MACE in Coronary CTO
Revascularization versus medication linked to reduced incidence of cardiac mortality, MACE
FRIDAY, Feb. 20, 2015 (HealthDay News) -- For patients with coronary chronic total occlusion (CTO) and well-developed collateral circulation, revascularization is associated with reduced risk of cardiac mortality and major adverse cardiac events (MACE), according to a study published in the Feb. 1 issue of JACC: Cardiovascular Interventions.
Woo Jin Jang, M.D., from Sungkyunkwan University School of Medicine in Seoul, South Korea, and colleagues compared the long-term clinical outcomes of patients with CTO and well-developed collateral circulation. Data were analyzed for 738 patients with Rentrop grade 3 collateral circulation. The incidence of cardiac death and MACE (composite of cardiac death, myocardial infarction, and repeat revascularization) was compared for 502 patients who underwent revascularization and medical therapy versus 236 who underwent medical therapy alone.
The researchers found that the incidence of cardiac death and MACE was significantly lower in the revascularization group versus the medication group (hazard ratios, 0.29 and 0.32; both P < 0.01) during a median follow-up of 42 months. The incidence of cardiac death (hazard ratio, 0.27; P = 0.02) and MACE (hazard ratio, 0.44; P = 0.01) remained significantly lower in the revascularization group versus the medication group, even after propensity score matching.
"In patients with coronary CTO and well-developed collateral circulation, aggressive revascularization may reduce the risk of cardiac mortality and MACE," the authors write.